biocon | Udaipur Kiran udaipurkiran.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from udaipurkiran.com Daily Mail and Mail on Sunday newspapers.
BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo. COVID-19 vaccine maker BioNTech, which is renewing its focus on its traditional roots in oncology, said in a joint statement with China's Duality that their drug would be tested on women with a certain type of advanced breast cancer with low levels of a cell surface receptor known as HER2. Partners Astra and Daiichi have taken the concept further with their leading drug Enhertu, based on the antibody-drug conjugate technology, a type of high-precision chemotherapy.
SABCS: Seagen outlines Tukysa s value alongside Roche s ADC in breast cancer But FDA path remains unclear fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.
Pfizer in March agreed to acquire Seagen and its targeted therapies in a $43 billion deal to help the drugmaker brace for a steep fall in COVID-19 product sales and generic competition for some top-selling drugs. Tuksya, along with Roche's Kadcyla, helped extend the time that patients with a type of breast cancer lived without their disease worsening. Kadcyla belongs to a class of drugs called antibody-drug conjugates (ADC), which have been described as "guided-missile" cancer drugs and the use